Tango Therapeutics TNGX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$45.51M-17.5% | -$38.75M-344% | $15.88M+141% | -$38.85M+2.6% | -$39.88M-5.9% | ||
| $463K-3.3% | $479K-13.7% | $555K-11.2% | $625K+0.5% | $622K+0.3% | ||
| $10.8M+80.6% | $5.98M-9.7% | $6.63M+0.8% | $6.57M-9.4% | $7.26M-2.8% | ||
| $1.79M+245% | -$1.23M— | —— | —— | $1.63M+165% | ||
| -$10K-177% | $13K— | $0-100% | $307K+30,800% | -$1K+88.9% | ||
| -$21K-211% | $19K+1,800% | $1K0.0% | $1K-98.2% | $56K— | ||
| —— | $0+100% | -$53.81M-1,592% | -$3.18M+41.0% | -$5.39M-31.0% | ||
| $972K+1.5% | $958K-1.5% | $973K-4.4% | $1.02M+0.6% | $1.01M+6.1% | ||
| -$44.36M-49.3% | -$29.72M+4.0% | -$30.95M+15.2% | -$36.52M+12.4% | -$41.7M-13.8% | ||
| -$2K-101% | $222K+47.0% | $151K-75.8% | $624K+1,124% | $51K-58.9% | ||
| $9.64M+107% | -$135.72M-386% | $47.48M+183% | $16.78M-45.2% | $30.6M-41.2% | ||
| $17.61M— | —— | —— | —— | $2K— | ||
| $79.85M-63.6% | $219.38M+8,533% | $2.54M+337% | $581K+28,950% | $2K-99.8% | ||
| $45.12M-16.4% | $53.94M+183% | $19.07M+200% | -$19.16M-72.6% | -$11.1M-168% | ||
| $463K-3.3% | $479K-13.7% | $555K-11.2% | $625K+0.5% | $622K+0.3% | ||
| $1.79M+245% | -$1.23M— | —— | —— | $1.63M+165% | ||
| -$8.69M-294% | $4.49M— | —— | —— | -$6.12M-511% | ||
| —— | $0+100% | -$53.81M-1,592% | -$3.18M+41.0% | -$5.39M-31.0% | ||
| -$781K+34.5% | -$1.19M-387% | -$245K+69.9% | -$814K-4.4% | -$780K+31.2% | ||
| $2.3M— | —— | $1.65M+48.8% | $1.11M+271% | -$649K— | ||
| $972K+1.5% | $958K-1.5% | $973K-4.4% | $1.02M+0.6% | $1.01M+6.1% | ||
| -$21K-211% | $19K+1,800% | $1K0.0% | $1K-98.2% | $56K— | ||
| $537K+5,867% | $9K0.0% | $9K0.0% | $9K0.0% | $9K— | ||
| —— | —— | —— | —— | —— | ||
| $17.61M— | —— | —— | —— | $2K— | ||
| —— | —— | —— | $248K+3,000% | $8K— | ||
| —— | —— | —— | —— | $1.31M+2,391% | ||
| —— | —— | —— | $1.12M+1,399% | $75K— | ||
| $1.45M-1.0% | $1.46M+212% | $468K-76.5% | $1.99M+3.0% | $1.94M+3.4% | ||
| -$44.36M-48.2% | -$29.94M+3.7% | -$31.1M+16.3% | -$37.14M+11.0% | -$41.75M-13.5% | ||
| -$44.36M-48.2% | -$29.94M+3.7% | -$31.1M+16.3% | -$37.14M+11.0% | -$41.75M-13.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Tango Therapeutics's cash flow data come from?
- Every line is extracted from Tango Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.